Literature DB >> 23576494

Cross-sectional and longitudinal associations between insulin-like growth factor I and metabolic syndrome: a general population study in German adults.

Nele Friedrich1, Matthias Nauck, Sabine Schipf, Henry Völzke, Georg Brabant, Henri Wallaschofski.   

Abstract

BACKGROUND: A previous study showed an inverse association between the insulin-like growth factor I (IGF-I) and the risk of impaired glucose tolerance or diabetes mellitus. Moreover, myocardial infarction patients with high baseline IGF-I levels had a lower risk of diabetes mellitus. These data suggested a protective effect of IGF-I against the development of metabolic syndrome. However, there are no longitudinal data regarding IGF-I and metabolic syndrome. The aim of the present study was to investigate the longitudinal association between IGF-I and metabolic syndrome.
METHODS: Data from the population-based Study of Health in Pomerania, Germany, were used for cross-sectional (n = 3903) and longitudinal (n = 2143) analyses (5-year follow-up). Metabolic syndrome was defined by three or more of the following five components: abdominal obesity, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure and elevated nonfasting glucose. Serum IGF-I and IGF binding protein 3 (IGFBP-3) were determined by chemiluminescence immunoassays. Logistic and Poisson regression analyses were performed to determine associations.
RESULTS: In cross-sectional analyses high IGFBP-3 as well as high and low IGF-I/IGFBP-3 ratio levels were associated with prevalent metabolic syndrome. In longitudinal analyses, the direction of the relation changed: men but not women with high IGF-I or IGF-I/IGFBP-3 ratio levels had an increased, whereas men with low levels had a decreased risk of incident metabolic syndrome.
CONCLUSION: In concordance with previous studies, our cross-sectional analyses showed a relation between low IGF-I/IGFBP-3 ratio and the prevalence of metabolic syndrome. In contrast, the longitudinal analyses indicated that a high IGF-I level was a risk marker for incident metabolic syndrome.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  IGF-I; IGFBP-3; Study of Health in Pomerania (SHIP); metabolic syndrome; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2013        PMID: 23576494     DOI: 10.1002/dmrr.2412

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  5 in total

1.  Impact of insulin like growth factor-1 in development of coronary artery ectasia.

Authors:  Ibrahim Faruk Akturk; Ismail Biyik; Ahmet Arif Yalcin; Nilgun Isiksacan; Omer Celik; Derya Ozturk; Mehmet Erturk
Journal:  Bosn J Basic Med Sci       Date:  2014-09-12       Impact factor: 3.363

2.  The relationship between serum-free insulin- like growth factor-1 and metabolic syndrome in school adolescents of northeast China.

Authors:  Shuang Xie; Ranhua Jiang; Wanfeng Xu; Yu Chen; Lei Tang; Ling Li; Ping Li
Journal:  Diabetes Metab Syndr Obes       Date:  2019-03-05       Impact factor: 3.168

3.  Investigation of insulin-like growth factors/insulin-like growth factor binding proteins regulation in metabolic syndrome patients.

Authors:  Somayeh Pouriamehr; Haleh Barmaki; Mozhdeh Rastegary; Farzaneh Lotfi; Mohsen Nabi Afjadi
Journal:  BMC Res Notes       Date:  2019-10-11

4.  Investigation of the Interplay between Circulating Lipids and IGF-I and Relevance to Breast Cancer Risk: An Observational and Mendelian Randomization Study.

Authors:  Vanessa Y Tan; Caroline J Bull; Kalina M Biernacka; Alexander Teumer; Tom G Richardson; Eleanor Sanderson; Laura J Corbin; Tom Dudding; Qibin Qi; Robert C Kaplan; Jerome I Rotter; Nele Friedrich; Uwe Völker; Julia Mayerle; Claire M Perks; Jeff M P Holly; Nicholas J Timpson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-09-28       Impact factor: 4.090

5.  Metabolic syndrome and body shape predict differences in health parameters in farm working women.

Authors:  Ilze Mentoor; Maritza Kruger; Theo Nell
Journal:  BMC Public Health       Date:  2018-04-04       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.